|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Crystal Bioscience and Open Monoclonal Technology Announce Human Antibody Strategic Alliance -- Open Monoclonal Technology Introduces "OmniAb™" Integrated Antibody Discovery Suite
12/4/2012 10:44:39 AM
PALO ALTO, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT) and Crystal Bioscience, Inc. (Crystal) today announced a strategic alliance where OMT will access Crystal’s deep antibody screening technology, Gel-Encapsulated Microenvironment (GEM. With this transaction, OMT formally launches “OmniAb™”, a new integrated antibody discovery suite with superior protein and DNA immunization, OMT’s proprietary OmniRat™ transgenic animals, and the GEM deep antibody screening technology. The GEM technology facilitates “minimal loss” identification of all antibodies with specific target and other therapeutically relevant characteristics across large lymphocyte populations and greatly reduces the time and cost associated with identification of candidate therapeutic antibodies. The assay involves bringing single antibody-secreting lymphocytes in proximity with cell or bead reporters within each GEM. The antibodies can diffuse locally within the GEM, bind to the reporters, and be detected visually or with secondary antibodies. Each GEM may contain multiple reporters for single-step differentiation of therapeutic features.
|
|
|
|
|
|
|
|
|
|
|